VANCOUVER, British Columbia, September 10th, 2020 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that they have been actively pursuing Joint Venture opportunities with several overseas companies including a strategic alliance with the University of Malaya Hospital to move forward with a compassionate human clinical trial (CT) before the end of 2020.

Read more ...

VANCOUVER, British Columbia, May 11, 2020 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) announces that it has entered into an agreement dated for reference March 30, 2020 with Sunfit Investments Ltd., to settle debt in the amount of $300,000 owed pursuant to a consulting agreement dated April 1, 2019 in exchange for the issuance of 1,000,000 common shares at a deemed price of 30 cents per share. All securities issued are subject to a statutory hold period expiring on September 12, 2020.

Read more ...

VANCOUVER, British Columbia, March 16th, 2020 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 5,990 shares at 12.639 CAD per share for gross proceeds of $75,707.  All dollar values are based on the published Exchange Rate of CAD0.001149/KRW1 on March 13, 2020, Bank of Canada. After the issuance of new BPK shares, CURE holds now 94.32% interest in BPK.

The net proceeds from the non-brokered private placement are intended to be used for general working capital and clinical trial of CAR T in Korea.

Read more ...

VANCOUVER, British Columbia, January 20th, 2020 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 53,567 shares at 12.375 CAD per share for gross proceeds of $662,892.  All dollar values are based on the published Exchange Rate of CAD0.001125/KRW1 on January 17, 2020, Bank of Canada. After the issuance of new BPK shares, CURE holds now 94.47% interest in BPK.

Read more ...

VANCOUVER, British Columbia, December 5th, 2019 -- BiocurePharm, Korea ("BPK"), a wholly owned subsidiary of Biocure Technology Corp. (CSE: CURE) (OTCQB: BICTF) ("CURE" or the "Company") is pleased to announce that it has closed its Convertible Debenture financing.  BPK has issued convertible debentures for gross proceeds of Korean Won660,000,000 (CAD732,600). Its maturity date is December 5, 2029, with the coupon rate of 3%. The investor has a right to convert to common shares of BPK at CAD12.21 per share three years after the issuance of Convertible Debenture. All dollar values are based on the published Exchange Rate of CAD0.001110/KRW1 on December 4, 2019, Bank of Canada.

Read more ...

Vancouver, British Columbia – October 17^h, 2019 – Biocure Technology Inc. (CSE: CURE OTCQB: BICTF) (the “Company” or “Biocure”) is pleased to announce that Biocure Pharm Corp.(“BPK”), a subsidiary of the Company has appointed CLIPS (Clinical Professional Services) as the CRO (Contract Research Organization) to proceed with a Clinical Trial for CAR-T products in Korea.   After reviewing multiple competent CRO’s in Korea and multiple meetings with them, BPK has selected CLIPS who has outstanding experience as well as expertise in gene therapies and cell therapies.  In addition, their knowledge of the clinical trials convinced BPK it could achieve a successful clinical trial for CAR-T products within the given timeline.

Read more ...

VANCOUVER, British Columbia, September 19th, 2019 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) wishes to correct its earlier press release of today’s date to advise that it has closed its Convertible Debenture financing through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued convertible debentures for gross proceeds of Korean Won440,000,000 (CAD490,160).  As previously advised, their maturity date is September 9, 2029 with the coupon rate of 3% and the investor has a right to convert to common shares of BPK at Korean Won11,000 (CAD12.25) per share three years after the issuance of Convertible Debenture.  All dollar values are based on the published Exchange Rate of CAD0.001114/KRW1 on September 18, 2019, Bank of Canada. 

Read more ...

VANCOUVER, British Columbia, July 10th, 2019 -- Biocure Technology Corp. (“CURE” or the “Company”) (CSE:CURE; OTCQB: BICTF) BiocurePharm, Korea (“BPK”), a wholly owned subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 60,404 shares at $10.898 CAD per share for gross proceeds of $658,258.63 (Korean Won591,959,200 @$0.001112 CAD/KW per Bank of Canada Exchange Rate). After the issuance of new BPK shares, CURE holds now 95.82% interest in BPK.

The net proceeds from the non-brokered private placement are intended to be used for general working capital and research and development.

Read more ...

Vancouver, British Columbia – May 16^h, 2019 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE OTCQB: BICTF) (the “Company” or “Biocure”) is pleased to announce that Biocure Pharm Corp.(“BPK”), a subsidiary of the Company has entered into an agreement with Pharos Vaccine Inc. for the development of overseas market  of CAR T-cell products on exclusive basis.

Read more ...

 Download the compiled report on pdf

Vancouver, British Columbia – April 11^th, 2019 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE OTCQB: BICTF) (the “Company” or “Biocure”) has granted an aggregate of 5,700,000 stock options to certain directors, officers, employees and consultants of the company. The options are exercisable at a price of $0,38 per share for a period of up to 3 years. The options and underlying common shares are subject to a four-month hold period in accordance with the policies of the Canadian Securities Exchange.

Read more ...

Vancouver, British Columbia – April 11^th, 2019 – Biocure Technology Inc. (formerly Gravis Energy Corp.) (CSE: CURE OTCQB: BICTF) (the “Company” or “Biocure”) has granted an aggregate of 5,700,000 stock options to certain directors, officers, employees and consultants of the company.

Read more ...